ANN LEBARON: Open Payments
NPI 1851354013 · GREENFIELD, WI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,233 in 127 payments from 17 companies in 2025. Trend: 2023 $1,562 · 2024 $1,633 · 2025 $2,233
Food & beverage: $2,226Education: $7
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $289 |
| Neurocrine BioSciences, Inc. | 15 | $267 |
| Teva Pharmaceuticals USA, Inc. | 11 | $256 |
| Vanda Pharmaceuticals Inc. | 20 | $222 |
| Otsuka America Pharmaceutical, Inc. | 11 | $197 |
| E.R. Squibb & Sons, L.L.C. | 9 | $184 |
| Lundbeck LLC | 8 | $154 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $136 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $131 |
| Axsome Therapeutics, Inc. | 5 | $90 |
Products named: REXULTI, VRAYLAR, INGREZZA, AUSTEDO XR, FANAPT, COBENFY, TRINTELLIX, CAPLYTA.
Industry payments across WI — which companies pay providers there.
